

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report: December 08, 2011**  
(Date of earliest event reported)

**ImmuCell Corporation**

(Exact name of registrant as specified in its charter)

**DE**  
(State or other jurisdiction  
of incorporation)

**001-12934**  
(Commission File  
Number)

**01-0382980**  
(IRS Employer  
Identification Number)

**56 Evergreen Drive**  
**Portland, Maine**  
(Address of principal executive offices)

**04103**  
(Zip Code)

**207-878-2770**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events**

ImmuCell Corporation (the “Company”) issued a press release regarding its Mast Out® product offering as presented at the World Animal Health Congress in Kansas City, MO. on December 8, 2011.

**Item 9.01. Financial Statements and Exhibits**

(c) Exhibits

99.1 Press Release of ImmuCell Corporation, dated December 8, 2011

99.2 White Paper: Treating Mastitis Without a Loss of Milk Revenue

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 8, 2011

**IMMUCELL CORPORATION**

By: /s/ Michael F. Brigham

Michael F. Brigham  
*President and CEO*

---

<b><u>Exhibit No.</u></b>	<b>Exhibit Index</b>	<b><u>Description</u></b>
99.1		Press Release of ImmuCell Corporation dated December 08, 2011
99.2		White Paper: Treating Mastitis Without a Loss of Milk Revenue

FOR IMMEDIATE RELEASE:

## IMMUCELL PRESENTS MAST OUT<sup>®</sup> PRODUCT OFFERING AT WORLD ANIMAL HEALTH CONGRESS

PORTLAND, Maine – December 8, 2011 -- **ImmuCell Corporation (NASDAQ: ICC)** is today presenting its **Mast Out<sup>®</sup>** product offering at the World Animal Health Congress at the Intercontinental Hotel in Kansas City, MO. **Mast Out** is a Nisin-based intramammary infusion product designed to treat subclinical mastitis without a milk discard or meat withhold requirement. Commercial introduction of **Mast Out** in the United States is subject to approval of a New Animal Drug Application (NADA) by the Center for Veterinary Medicine, US Food and Drug Administration (FDA), which approval cannot be assured.

“We welcome the opportunity to share the latest information regarding this novel product offering with this diverse audience of animal health companies and financiers,” commented Michael F. Brigham, President and CEO. “The desired partner would participate with us in completing the commercial manufacturing obligations and preparing the product for market launch.”

A White Paper detailing the product opportunity and the status of the **Mast Out** NADA was published in the World Animal Health Congress Conference Documentation Book, a publication distributed to the conference attendees. Interested parties may also obtain a copy of the White Paper on the ImmuCell corporate website.

As detailed in ImmuCell’s recent filings with the Securities and Exchange Commission, all initial submissions to the FDA have been made for all Technical Sections under the NADA with the exception of the Chemistry, Manufacturing and Controls (CMC) Section. Approval of the CMC section, which describes the manufacturing process for the applicable sites, is now the critical path to FDA approval. Final approval of this section requires the submission of documentation from three full-scale manufacturing batches.

The company has initiated its planned search for a commercialization partner to fund and support this effort. ImmuCell recently engaged Axxiom LLC, a strategic consulting firm, to assist with the efforts to finalize selection of a commercialization partner for this major product development initiative.

Chris Ragland, Managing Principal for Axxiom, commented, “**Mast Out** is a great example of a positive paradigm shift in food animal production medicine. While **Mast Out** remains under review at the FDA, data from clinical field trials have been encouraging in demonstrating **Mast Out** to be a safe and effective treatment option for target mastitis pathogens. This innovation in mastitis management would replace the use of traditional antibiotics in the treatment of subclinical mastitis and assure no loss of income due to milk discard. With **Mast Out**, ImmuCell would bring an entirely new approach for mastitis management to the dairy industry. We at Axxiom are pleased to have the opportunity to support the ImmuCell team in their efforts to secure the right commercial partner for this important new product.”

About ImmuCell:

ImmuCell Corporation’s (NASDAQ: ICC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (<http://www.immucell.com>).

**Contact:** Michael F. Brigham, President and Chief Executive Officer  
(207) 878-2770 Ext. 3106

### **Forward-Looking Statement Disclaimer**

*The foregoing press release as well as the above referenced White Paper and conference presentation contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause the Company's future results to differ materially from those described in the forward-looking statements, together with other risk factors, are detailed from time to time in filings made with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Forward-looking statements are based on our current information and expectations. Actual results may differ materially due to various factors, including those risks.*

###

